USPTO serial 79329198
RENMICE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 3, 2024
- Examiner
- KEAM, ALEX S
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with RENMICE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
CN
Other trademarks owned by Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
CN
Other trademarks owned by Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
CN
Other trademarks owned by Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Karen Feisthamel
Karen Feisthamel KDB Firm PLLC2601 Weston Parkway, Suite 1031Cary, NC 27513UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines for human purposes for the treatment of tumors, infectious diseases, inflammation and autoimmune diseases; diagnostic preparations for medical and veterinary purposes; biological preparations for medical purposes for the treatment of tumors, infectious diseases, inflammation and autoimmune diseases; active pharmaceutical ingredients, namely, antibodies for the treatment of human and animal diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of cancer; biochemical medicines for the treatment of tumors, infectious diseases, inflammation and autoimmune diseases; vaccines; dietetic preparations adapted for medical use; medicines for veterinary purposes for the treatment of tumors, infectious diseases, inflammation and autoimmune diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Other trademarks owned by Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Other trademarks owned by Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Other trademarks in Class 005
- Similar marks named RENMICE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 26, 2025 | Further Decision Processed by IB | — | |
| Feb 15, 2025 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Feb 15, 2025 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Dec 3, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Sep 3, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Sep 3, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 20, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jun 18, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 18, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 11, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 11, 2024 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| May 29, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 15, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 2, 2024 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Apr 2, 2024 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Apr 2, 2024 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Mar 25, 2024 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Sep 21, 2023 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jun 12, 2023 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| May 24, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| May 24, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Mar 28, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 24, 2023 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Mar 24, 2023 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Mar 24, 2023 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Mar 23, 2023 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Mar 23, 2023 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Mar 1, 2023 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Mar 1, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 1, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 1, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 1, 2023 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Sep 27, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 3, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 3, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 1, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 31, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 27, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 7, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 3, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 23, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |